Plain English Summary
Background and study aims
The IntelliCap capsule is a swallowable, electronic, capsule-shaped device. It holds a liquid drug payload. The capsule contains sensors (for acidity and temperature), a battery, a microprocessor, a small motor, and electronics for wireless, real-time communication with an external receiver. When swallowed, it travels through the gut with its natural movement and is excreted with a bowel movement. Real-time data from its sensors are used to locate the capsule within the gut. Upon command, the capsule releases its liquid drug payload in a controlled way over time by the action of a small motor. The study aims to explore the levels of this marker drug in blood when released from the IntelliCap capsule in a pre-programmed way over time compared to a marketed drug capsule.
Who can participate?
Adult men who are healthy as determined by an upfront health check, can participate in the study.
What does the study involve?
Participants are asked to swallow one IntelliCap capsule and a marketed drug capsule in a random order with an interval of one week in between. Blood samples are taken over time to find out the levels of the drug. They have to stay at the clinic each time for about 2 days. Additional assessments are made to monitor safety. After completion, participants have to return to the clinic for a final assessment. Those swallowing an IntelliCap capsule have to wear a mobile phone-size device around their waist that communicates between the IntelliCap capsule in the body and a computer. They have to collect their stool and recover the excreted IntelliCap capsule that is then returned to the clinic.
What are the possible benefits and risks of participating?
No particular benefit is expected or intended for participants. Drug-related risks include swelling of ankles, decrease in the blood pressure, slow heartbeat, upset stomach, dizziness, facial flushing, headache, light-headedness, skin irritation (rash), tiredness and weakness. Capsule may get stuck in the bowels or the capsule may come apart and could injure the bowels.
Where is the study run from?
ProMedica Clinical Research Center, Brighton, USA.
When is the study starting and how long is it expected to run for?
Recruitment of healthy volunteers for this study started in December 2011 and the study ended in January 2012.
Who is funding the study?
Medimetrics Personalized Drug Delivery Inc., USA.
Who is the main contact?
Dr Christoph Wanke
christoph.wanke@medimetrics.com
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
iPS-110077
Study information
Scientific title
An open-label, randomized, two-period crossover study to explore the pharmacokinetics of diltiazem solution released from the IntelliCap as compared to a marketed diltiazem 60 mg extended release capsule in healthy volunteers
Acronym
Study hypothesis
The aim of the study is to explore the pharmacokinetics in healthy volunteers of diltiazem when released as a solution from the IntelliCap capsule with a defined release profile as compared to a marketed extended release capsule.
Ethics approval
New England Institutional Review Board, 23/11/2011, IRB# 11-361
Study design
Randomized open-label two-period crossover study
Primary study design
Interventional
Secondary study design
Randomised cross over trial
Trial setting
Other
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Pharmaceutical research and development
Intervention
14 male, healthy volunteers at a single site will undergo both of the following interventions in a randomized order with a wash-out period in between of at least 7 days:
1. IntelliCap capsule: payload diltiazem HCl aqueous solution (270 mg/mL), programmed to dispense 60 mg over 24 hours with a first order release profile
2. Diltiazem Hydrochloride Extended-Release capsules USP (60 mg, Cardizem SR®, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, USA)
Subjects have to stay at the clinical center each time for about 2 days. After completion of the treatments, subjects have to return to the clinical center for a final assessment.
Intervention type
Drug
Phase
Not Applicable
Drug names
Diltiazem
Primary outcome measures
Pharmacokinetics of diltiazem released from the IntelliCap as compared to a marketed extended release capsule (AUClast, AUC0-t, AUC∞, Cmax, Tmax, Tlag, T1/2). Blood collection for diltiazem (parent) bioanalysis: pre-administration, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 24, 36, 48 h post-administration. Diltiazem is determined in plasma by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method, lower limit of quantification (LLOQ) at 0.2 ng/mL using 200 μL plasma.
Secondary outcome measures
1. Adverse events, adverse device effects (number, severity)
2. Physical examination: Day -1 in each period, end of study visit (> 4 days after last administration)
3. Vital signs and body measurements: body weight, oral body temperature: Day -1 in each period, end of study visit. Systolic and diastolic blood pressure and pulse rate: Day -1, pre-administration, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 h post-administration, end of study visit (> 4 days after last administration)
4. ECG evaluation: Day -1 in each period, end of study visit (> 4 days after last administration)
5. Standard clinical laboratory evaluation (hematology: hemoglobin, hematocrit, WBC count with differential (monocytes, eosinophils, basophils, neutrophils, lymphocytes) as absolute value, RBC count and platelet count. Blood chemistry: albumin, alkaline phosphatase, bilirubin (total, direct and indirect), bicarbonate/CO2, calcium, cholesterol, chloride, creatinine, CK, gamma-GT, glucose, LDH, inorganic phosphorus, lipase, amylase, magnesium, potassium, total protein, AST, ALT, sodium, triglycerides, urea/BUN and uric acid. Urinalysis: specific gravity, pH; semi-quantitative 'dipstick' evaluation of glucose, protein, bilirubin, ketones, leukocytes, blood): Day -1 in each period, 24 h post-administration, end of study visit (> 4 days after last administration)
Overall trial start date
27/12/2011
Overall trial end date
23/01/2012
Reason abandoned
Eligibility
Participant inclusion criteria
1. Provision of informed consent
2. Healthy male subjects age 18 to 45 years of age inclusive
3. Vital signs: body temperature between 35.0 and 37.5 °C, systolic blood pressure 90-140 mmHg, diastolic blood pressure 60-90 mmHg, pulse rate 50-90 bpm
4. Body weight > 50 kg, BMI 18 to 29 kg/m2
Participant type
Patient
Age group
Adult
Gender
Male
Target number of participants
14
Participant exclusion criteria
1. Smoking
2. Use of prescription drugs, herbal supplements, over the counter medication
3. Significant ECG (electrocardiogram) abnormalities
4. Surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs
5. Impaired renal function
6. Pacemakers or other implanted electro-medical devices
7. Swallowing disorder
8. Scheduled MRI assessment
Recruitment start date
27/12/2011
Recruitment end date
23/01/2012
Locations
Countries of recruitment
United States of America
Trial participating centre
HighTech Campus 5-2.041
Eindhoven
5656 AE
Netherlands
Sponsor information
Organisation
Medimetrics Personalized Drug Delivery B.V. (Netherlands)
Sponsor details
c/o Christoph Wanke
HighTech Campus 5-2.041
Eindhoven
5656 AE
Netherlands
Sponsor type
Industry
Website
Funders
Funder type
Industry
Funder name
Medimetrics Personalized Drug Delivery Inc. (USA)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/25023947